BioAge Labs has raised $170 million in Series D funding to enhance therapies for obesity and metabolic diseases. The round was led by Sofinnova Investments with participation from both new and existing investors. 

The funds will support Phase 2 trials of azelaprag, an apelin receptor agonist, in combination with Eli Lilly's Zepbound to improve obesity treatment outcomes, with initial results having shown potential in increasing muscle metabolism and preventing atrophy. 

The following article originally appeared in Pharmaceutical Technology.

BioAge Labs has secured $170m in an oversubscribed Series D funding round to progress the development of therapeutics for obesity and metabolic diseases.

The financing was led by Sofinnova Investments. It included contributions from a consortium of new investors including RA Capital, Longitude Capital and Cormorant Asset Management, and from existing investors such as Andreessen Horowitz (a16z) Bio + Health.

Sofinnova Investments managing partner James Healy will assume the role of board chairman at BioAge, while Longitude Capital managing director Patrick Enright will join as a board director.

The investment will enable BioAge to advance Phase II clinical trials of its drug candidate, azelaprag, an oral apelin receptor agonist being developed for use along with Eli Lilly’s Zepbound (tirzepatide) and other incretins to enhance obesity treatment outcomes.

The upcoming studies with Zepbound will begin in mid-2024, in collaboration with Eli Lilly’s Chorus organisation.

For more, please find the original story source here.